Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed SCLC in China September 16, 2026
Ph 3 data for Tam-Peli shows significantly improved OS in Chinese patient population with relapsed SCLC September 16, 2026
Imfinzi + Imdelltra demonstrated statistically significant OS & PFS improvement in 1L ES-SCLC September 9, 2026
Successful FDA Type C Meeting conducted for IDE849 on Ph 3 Registrational Trial Design for Potential Accelerated and Full Approval in ES-SCLC September 2, 2026
ACR-2316 advances into dose expansion portion of Ph 1/2 study in SCLC, squamous NSCLC, lung adenocarcinoma (adNSCLC), endometrial, cervical, and GEJ cancers August 11, 2026
HETRONIFLY (serplulimab) recommended by the NICE for routine use within the NHS in England and Wales July 7, 2026
FAILED TRIAL: Ph 3 LAGOON trial of Zepzelca in patients with 2L SCLC did not meet primary endpoint of OS June 17, 2026
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload May 26, 2026
Boehringer Ingelheim and Zai Lab announce collaboration on DLL3‑targeting T‑Cell Engager and ADC combination in SCLC and other Neuroendocrine Carcinomas April 21, 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated ES-SCLC who Experienced Disease Progression on or After Platinum-Based Chemotherapy April 21, 2026
ZEPZELCA + Tecentriq approved for use in Australia and Singapore as 1L maintenance treatment for adult patients with ES-SCLC April 21, 2026
Ifinatamab Deruxtecan Granted Priority Review in the US for Adult Patients with Previously Treated ES-SCLC April 15, 2026
Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Ph 1b/2 trial of obrixtamig with pumitamig in ES-SCLC April 15, 2026
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate Zocilurtatug Pelitecan in Combination with Imdelltra April 7, 2026
Summit Therapeutics and GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 ADC January 18, 2026
AbbVie secured global rights outside China to ZG006 (alveltamig) developed by Suzhou Zelgen Biopharmaceuticals January 4, 2026
